Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Movement disorders

Vascular endothelial growth factor alleviates spinocerebellar ataxia type 1 in mice

Nature Reviews Neurology volume 8, page 3 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

Spinocerebellar ataxia type 1 (SCA1) is caused by a CAG repeat expansion in the ataxin-1 (ATXN1) gene. Experiments in a mouse model of SCA1 have now shown that the mutant ATXN1 protein represses transcription of the gene that encodes vascular endothelial growth factor (VEGF), and that overexpression or infusion of VEGF improves motor function in this animals. The authors propose that VEGF could represent a novel therapeutic strategy for SCA1.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Cvetanovic, M. et al. Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat. Med. 17, 1445–1447 (2011)

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vascular endothelial growth factor alleviates spinocerebellar ataxia type 1 in mice. Nat Rev Neurol 8, 3 (2012). https://doi.org/10.1038/nrneurol.2011.197

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.197

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research